Levovir
(Clevudine)PreclinicalSmall molecule
Clevudine is used to treat chronic hepatitis B, a viral infection that affects the liver. It works by slowing down the virus's ability to reproduce.[1] Levovir is currently being investigated across 1 indication[3], with its most advanced program in Preclinical.[1]
Levovir is one of 52 small molecule programs targeting Viral Disease. It is currently in Preclinical.
1
Indications
23
Total Trials
0
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Viral Disease
#DrugCompanyPhaseTrials
1Tivicay
GSKApproved
Cabenuva
GSKApproved
Tyzeka
NovartisApproved
Hepsera
GileadApproved
Vemlidy
GileadApproved
Viread
GileadApproved
Vistide
GileadApproved
Incivek
Vertex PharmaceuticalsApproved
Ziagen
GSKApproved
Sunlenca
GileadApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis8 trials
Show 5 more trials
Safety and Efficacy4 trials
Chronic3 trials
COVID-192 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Clevudine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Protein P Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBukwang Pharmaceutical